Drug
Abobotulinumtoxina
Abobotulinumtoxina: highest development phase Post-Market, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| AbobotulinumtoxinA NCT05466539 | Post-Market | Compartment Syndrome of Leg |
Latest
No recent events.
Follow Abobotulinumtoxina on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.